2026 · Digestive diseases and sciences · paywalled
Patient Perspectives to Inform Co-creation of Wearable-Derived Digital Biomarkers for Early Flare Detection and Management in IBD: A Survey-Based Study
Godecharle et al.
The finding, in our words
In a nationwide survey of 1,080 individuals with inflammatory bowel disease, 88% viewed remote flare detection as potentially useful and over 90% believed wearables could support this purpose. Smartwatches were identified as the preferred wearable modality, highlighting strong patient willingness to adopt digital biomarkers for continuous disease surveillance.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
Merck describes a digitally enabled, patient-centric trial initiative that combines outpatient PK/PD sampling with digital biomarkers and smart dosing technologies to improve exposure-response understanding and reduce patient burden, while acknowledging adoption challenges.
Dockendorf et al., Clinical and translational science · source ↗
A hybrid decentralised clinical trial using wearable dosing-monitoring and remote adverse-event reporting in healthy adults achieved 100% adherence with only 2% missing data, maintained adverse-event detection sensitivity, and was rated less burdensome than conventional on-site visits. These findings support the feasibility and reliability of participant-centric remote monitoring in early-phase pharmacokinetic studies.
Kim et al., Clinical and translational science · source ↗
A direct-to-participant, multichannel recruitment strategy enrolled 34,244 older adults into a virtual trial testing an Apple Watch based heart health programme with electrocardiogram and irregular rhythm notification features, achieving broad geographic and gender diversity but under-representing non-White ethnic groups.
Analysis of six studies revealed that decentralised clinical trial elements enhanced data completeness by enabling direct access to medical records, although this introduced a significant burden for data abstraction. The results suggest that decentralised approaches are not a universal solution but provide specific metrics that can help design fit-for-purpose trials.
Wearable-derived digital biomarkers have been accepted by regulatory agencies as endpoints in clinical trials for Duchenne muscular dystrophy, showing their potential to support decentralised diagnostics through patient-centric monitoring. This matters because it enables more sensitive and continuous assessment of disease progression outside clinical settings.
Ma et al., Neurology and therapy (paywalled) · source ↗